Clinicopathological comparison between PTCL-TBX21 and PTCL-GATA3 in Japanese patients
© 2023 The Authors. Cancer Medicine published by John Wiley & Sons Ltd..
AIM: Peripheral T-cell lymphoma not otherwise specified (PTCL-NOS) is a heterogeneous disease that can be classified into the PTCL-TBX21 and PTCL-GATA3 subtypes.
METHODS: In this study, we compared the clinicopathological features of PTCL-NOS in a Japanese cohort, classified using an IHC algorithm.
RESULTS: One hundred patients with PTCL-NOS were categorized as having PTCL-TBX21 (n = 55), PTCL-GATA3 (n = 24), or PTCL-unclassified (n = 21). When comparing PTCL-TBX21 and PTCL-GATA3, PTCL-TBX21 showed significantly lower CD4 positivity (p = 0.047), lower counts of high endothelial venules (p = 0.032), and a tendency for a better response to initial treatment (p = 0.088). Gene expression analysis using the nCounter system showed higher expression of tumor immunity-related genes, such as PD-L1, LAG3, and IDO1, in PTCL-TBX21 than in PTCL-GATA3. PTCL-GATA3 had significantly worse overall survival (OS) than those with PTCL-TBX21 (p = 0.047), although a similar tendency was observed for progression-free survival (PFS) (p = 0.064). PTCL-GATA3 was a prognostic factor for OS in univariate analysis (HR 2.02; 95% CI, 1.09-3.77; p = 0.027), although multivariate analysis did not show significance (HR 2.07; 95% CI, 0.93-4.61; p = 0.074). In the PFS analysis, PTCL-GATA3 was an independent prognostic factor by univariate analysis (HR 1.96; 95% CI, 1.08-3.56; p = 0.027) and multivariate analysis (HR 2.34; 95% CI, 1.07-5.11; p = 0.032).
CONCLUSION: The classification of PTCL-NOS into PTCL-TBX21 and PTCL-GATA3 is useful for predicting the prognosis of Japanese patients and stratifying the administration of tumor immune checkpoint inhibitors in clinical practice.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:13 |
|---|---|
| Enthalten in: |
Cancer medicine - 13(2024), 3 vom: 01. Feb., Seite e6793 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Shimasaki, Yasumasa [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
GATA3 Transcription Factor |
|---|
| Anmerkungen: |
Date Completed 04.03.2024 Date Revised 04.03.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1002/cam4.6793 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM367247275 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM367247275 | ||
| 003 | DE-627 | ||
| 005 | 20240304232303.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240118s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/cam4.6793 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1316.xml |
| 035 | |a (DE-627)NLM367247275 | ||
| 035 | |a (NLM)38234210 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Shimasaki, Yasumasa |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Clinicopathological comparison between PTCL-TBX21 and PTCL-GATA3 in Japanese patients |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 04.03.2024 | ||
| 500 | |a Date Revised 04.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. | ||
| 520 | |a AIM: Peripheral T-cell lymphoma not otherwise specified (PTCL-NOS) is a heterogeneous disease that can be classified into the PTCL-TBX21 and PTCL-GATA3 subtypes | ||
| 520 | |a METHODS: In this study, we compared the clinicopathological features of PTCL-NOS in a Japanese cohort, classified using an IHC algorithm | ||
| 520 | |a RESULTS: One hundred patients with PTCL-NOS were categorized as having PTCL-TBX21 (n = 55), PTCL-GATA3 (n = 24), or PTCL-unclassified (n = 21). When comparing PTCL-TBX21 and PTCL-GATA3, PTCL-TBX21 showed significantly lower CD4 positivity (p = 0.047), lower counts of high endothelial venules (p = 0.032), and a tendency for a better response to initial treatment (p = 0.088). Gene expression analysis using the nCounter system showed higher expression of tumor immunity-related genes, such as PD-L1, LAG3, and IDO1, in PTCL-TBX21 than in PTCL-GATA3. PTCL-GATA3 had significantly worse overall survival (OS) than those with PTCL-TBX21 (p = 0.047), although a similar tendency was observed for progression-free survival (PFS) (p = 0.064). PTCL-GATA3 was a prognostic factor for OS in univariate analysis (HR 2.02; 95% CI, 1.09-3.77; p = 0.027), although multivariate analysis did not show significance (HR 2.07; 95% CI, 0.93-4.61; p = 0.074). In the PFS analysis, PTCL-GATA3 was an independent prognostic factor by univariate analysis (HR 1.96; 95% CI, 1.08-3.56; p = 0.027) and multivariate analysis (HR 2.34; 95% CI, 1.07-5.11; p = 0.032) | ||
| 520 | |a CONCLUSION: The classification of PTCL-NOS into PTCL-TBX21 and PTCL-GATA3 is useful for predicting the prognosis of Japanese patients and stratifying the administration of tumor immune checkpoint inhibitors in clinical practice | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a PTCL-GATA3 | |
| 650 | 4 | |a PTCL-TBX21 | |
| 650 | 4 | |a pathology | |
| 650 | 4 | |a peripheral T-cell lymphoma not otherwise specified | |
| 650 | 7 | |a Immune Checkpoint Inhibitors |2 NLM | |
| 650 | 7 | |a GATA3 protein, human |2 NLM | |
| 650 | 7 | |a GATA3 Transcription Factor |2 NLM | |
| 700 | 1 | |a Miyoshi, Hiroaki |e verfasserin |4 aut | |
| 700 | 1 | |a Kawamoto, Keisuke |e verfasserin |4 aut | |
| 700 | 1 | |a Yoshida, Noriaki |e verfasserin |4 aut | |
| 700 | 1 | |a Mishina, Tatsuzo |e verfasserin |4 aut | |
| 700 | 1 | |a Nakashima, Kazutaka |e verfasserin |4 aut | |
| 700 | 1 | |a Imamoto, Teppei |e verfasserin |4 aut | |
| 700 | 1 | |a Sugio, Takeshi |e verfasserin |4 aut | |
| 700 | 1 | |a Yanagida, Eriko |e verfasserin |4 aut | |
| 700 | 1 | |a Kato, Takeharu |e verfasserin |4 aut | |
| 700 | 1 | |a Yamada, Kyohei |e verfasserin |4 aut | |
| 700 | 1 | |a Takeuchi, Mai |e verfasserin |4 aut | |
| 700 | 1 | |a Suzuki, Takaharu |e verfasserin |4 aut | |
| 700 | 1 | |a Moritsubo, Mayuko |e verfasserin |4 aut | |
| 700 | 1 | |a Furuta, Takuya |e verfasserin |4 aut | |
| 700 | 1 | |a Imaizumi, Yoshitaka |e verfasserin |4 aut | |
| 700 | 1 | |a Takizawa, Jun |e verfasserin |4 aut | |
| 700 | 1 | |a Kato, Koji |e verfasserin |4 aut | |
| 700 | 1 | |a Suzumiya, Junji |e verfasserin |4 aut | |
| 700 | 1 | |a Suzuki, Ritsuro |e verfasserin |4 aut | |
| 700 | 1 | |a Ohshima, Koichi |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Cancer medicine |d 2012 |g 13(2024), 3 vom: 01. Feb., Seite e6793 |w (DE-627)NLM224388460 |x 2045-7634 |7 nnns |
| 773 | 1 | 8 | |g volume:13 |g year:2024 |g number:3 |g day:01 |g month:02 |g pages:e6793 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1002/cam4.6793 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 13 |j 2024 |e 3 |b 01 |c 02 |h e6793 | ||